The identification of a subtype of pancreatic cancer initiated by PIK3CA mutations is an exciting advance as there is great potential for patients with cancers carrying these mutations to benefit from targeted therapies. This evidence concerns the gene PIK3CA and familial pancreatic carcinoma.